Leqembi

Leqembi. It is a monoclonal antibody therapy developed for the treatment of Alzheimer's disease. The drug targets amyloid beta plaques in the brain, which are a hallmark pathological feature of the neurodegenerative condition. Its development and regulatory approval have been significant events in the field of neurology and pharmacology.

Medical uses

Leqembi is indicated for the treatment of mild cognitive impairment or mild dementia stage of Alzheimer's disease. Its use is specifically for patients with confirmed presence of amyloid beta pathology, typically verified through positron emission tomography or cerebrospinal fluid analysis. The therapy is not intended for use in later stages of the disease, such as moderate dementia or severe dementia. Administration occurs via intravenous therapy in a clinical setting under the supervision of a healthcare professional.

Mechanism of action

This humanized immunoglobulin G1 monoclonal antibody selectively binds to soluble amyloid beta protofibrils and insoluble amyloid beta plaques. By binding to these forms, it facilitates their clearance by engaging the body's innate immune system, particularly microglia. This action is believed to reduce the overall amyloid plaque burden in critical brain regions like the cerebral cortex and the hippocampus. The reduction in amyloid is correlated with a slowing of clinical decline in measures of cognition and function.

Adverse effects

Common adverse reactions include amyloid related imaging abnormalities (ARIA), which can manifest as edema or microhemorrhages detectable on magnetic resonance imaging. Infusion-related reactions, such as nausea, fever, and hypotension, are also frequently reported. Serious risks involve symptomatic ARIA, presenting as headache, confusion, dizziness, and vision changes. The prescribing information includes a warning for a potential increased risk of cerebral hemorrhage, particularly in patients on concurrent antithrombotic agents like warfarin.

Clinical trials

The pivotal Phase 3 trial, known as Clarity AD, was a global, double-blind, placebo-controlled study conducted by Eisai and Biogen. It enrolled participants with early Alzheimer's disease across sites in North America, Europe, and Asia. The primary endpoint was change on the Clinical Dementia Rating–Sum of Boxes scale over 18 months. Results showed a statistically significant slowing of cognitive and functional decline compared to placebo. Earlier phase studies, including the Phase 2 proof-of-concept trial, helped establish the dosing regimen and provided initial evidence of amyloid plaque reduction.

Society and culture

The approval of Leqembi by the U.S. Food and Drug Administration under the accelerated approval pathway and later traditional approval was a major media event, covered extensively by outlets like The New York Times and CNN. Its high annual cost has sparked significant debate about Medicare coverage, healthcare economics, and drug pricing in the United States. The therapy has been discussed in the context of the long, challenging history of amyloid hypothesis-targeting drugs, following the controversial approval of aducanumab.

History and development

The drug, with the generic name lecanemab, originated from a research collaboration between Eisai and BioArctic of Sweden. The scientific foundation stems from decades of research into the amyloid cascade hypothesis, first prominently articulated by John Hardy and Dennis Selkoe. Following the completion of the Clarity AD trial, Eisai submitted data to regulatory bodies worldwide, including the FDA, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency. The FDA granted traditional approval in July 2023, a decision informed by the recommendation of its Peripheral and Central Nervous System Drugs Advisory Committee. Category:Monoclonal antibodies Category:Alzheimer's disease medications Category:Eisai